Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from MYND Life Sciences ( (TSE:MYND) ) is now available.
MYND Life Sciences Inc. announced that it has been granted a management cease trade order (MCTO) due to a delay in finalizing its annual consolidated financial statements for the year ended October 31, 2024. This delay is attributed to significant restructuring of the company’s debt and equity, preventing the company from meeting the filing deadline of February 28, 2025. The MCTO restricts trading by the company’s CEO and CFO but does not affect other shareholders. The company plans to complete the required filings by April 29, 2025, and is currently on the defaulting issuers list of the British Columbia Securities Commission. Despite this, MYND confirms there has been no material change in its operations or intentions, and it will continue to provide updates on the status of its filings.
More about MYND Life Sciences
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, and diagnostics. The company is engaged in developing new biological entities (NBEs) and new chemical entities (NCEs), leveraging unique molecular concepts for the application of psilocybins to overcome diseases. MYND advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property.
YTD Price Performance: -83.33%
Average Trading Volume: 6,103
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.01M
See more insights into MYND stock on TipRanks’ Stock Analysis page.